Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.

Terminated Impurity / degradation Ascend Laboratories LLC NDC 67877-545-68 D-0264-2021
Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.

Terminated Impurity / degradation Ascend Laboratories LLC NDC 67877-545-88 D-0263-2021
Class II · Moderate risk

Lidocaine/Tetracaine

Superpotent Drug. Lidocaine higher concentration than listed

Terminated Wrong potency / content Stanley Specialty Pharmacy Compounding and Wellness Center D-0252-2021
Class II · Moderate risk

Famotidine Tablets USP 40mg

Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.

Terminated Particulate / foreign matter Aurobindo Pharma USA Inc. NDC 65862-860-99 D-0290-2021
Class II · Moderate risk

Sulfur Ointment 10%

Labeling: Label Mix-Up. THe English label with Drug Facts panel for Camphor was incorrectly placed on product.

Terminated Labeling / mix-up DLC Laboratories, Inc D-0257-2021
Class II · Moderate risk

Levetiracetam Oral Solution

Defective container: Customer complaints for oral solution leaking from bottles.

Terminated Packaging defect Akorn, Inc. NDC 50383-241-16 D-0221-2021
Class II · Moderate risk

IMC Wash-Free Hand Sanitizer

CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.

Terminated Chemical / undeclared Shane Erickson Inc D-0241-2021
Class II · Moderate risk

IMC Wash-Free Hand Sanitizer

CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.

Terminated Chemical / undeclared Shane Erickson Inc D-0240-2021
Class II · Moderate risk

IMC Wash-Free Hand Sanitizer

CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.

Terminated Chemical / undeclared Shane Erickson Inc D-0239-2021
Class II · Moderate risk

Zerbaxa (ceftolozane and tazobactam)

Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. While all product distributed to the market has met the registered specifications for release, including for sterility, it was manufactured on the same equipment as the affected batches.

Terminated Sterility / contamination Merck Sharp & Dohme NDC 67919-030-01 D-0176-2021

Recalls by year